{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:27:44Z","timestamp":1777418864146,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800044C"],"award-info":[{"award-number":["HHSN272201800044C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2025.126707","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:48:29Z","timestamp":1736531309000},"page":"126707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine"],"prefix":"10.1016","volume":"47","author":[{"given":"Yoshikazu","family":"Honda-Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utsav","family":"Vaghasiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126707_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4161\/hv.2.1.2554","article-title":"Vaccine development for an imminent pandemic: why we should worry, what we must do","volume":"2","author":"Fedson","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2025.126707_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01311693","article-title":"Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A\/seal\/Massachusetts\/1\/80 (H7N7) influenza virus","volume":"76","author":"Kida","year":"1983","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2025.126707_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0168-1702(86)90004-3","article-title":"Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody","volume":"4","author":"Yoden","year":"1986","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2025.126707_bb0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.126707_bb0025","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126707_bb0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","article-title":"Confronting the avian influenza threat: vaccine development for a potential pandemic","volume":"4","author":"Stephenson","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126707_bb0035","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126707_bb0040","doi-asserted-by":"crossref","first-page":"1105655","DOI":"10.3389\/fimmu.2023.1105655","article-title":"Review: current trends, challenges, and success stories in adjuvant research","volume":"14","author":"Singleton","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126707_bb0045","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126707_bb0050","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","article-title":"Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets","volume":"29","author":"Layton","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126707_bb0055","doi-asserted-by":"crossref","first-page":"2363016","DOI":"10.1080\/21645515.2024.2363016","article-title":"Clinical development of SpikoGen(R), an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine","volume":"20","author":"Petrovsky","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126707_bb0060","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.vaccine.2024.02.073","article-title":"Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: a double-blind, non-inferiority, randomized controlled trial","volume":"42","author":"Yadegarynia","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126707_bb0065","first-page":"151","article-title":"Sampling variation of the fifty percent end-point, determined by the reed-Muench (Behrens) method","volume":"22","author":"Pizzi","year":"1950","journal-title":"Hum Biol"},{"key":"10.1016\/j.vaccine.2025.126707_bb0070","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1038\/s41598-018-29858-w","article-title":"Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126707_bb0075","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jix478","article-title":"Randomized comparison of immunogenicity and safety of Quadrivalent recombinant versus inactivated influenza vaccine in healthy adults 18-49 years of age","volume":"216","author":"Dunkle","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126707_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126707_bb0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/erv.11.24","article-title":"Insect cell technology is a versatile and robust vaccine manufacturing platform","volume":"10","author":"Mena","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126707_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.126707_bb0095","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126707_bb0100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/imcb.12774","article-title":"Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a cellular receptor for delta inulin adjuvant","volume":"102","author":"Stewart","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2025.126707_bb0105","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans--on the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:23:55Z","timestamp":1740270235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":21,"alternative-id":["S0264410X25000040"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126707","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126707"}}